DAXOR CORPORATION - CLOSED END FUND

Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023

28 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®

10 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire

JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

12 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.

11 июл 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer

05 июл 2023 08:00:00 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering

22 июн 2023 16:15:00 Источник Nasdaq GlobeNewswire

Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting

20 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services

15 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference

12 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering

25 май 2023 15:37:00 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering

22 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Proposed Underwritten Public Offering

19 май 2023 16:53:00 Источник Nasdaq GlobeNewswire

New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

18 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

20 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring’23 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)

17 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

13 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients

27 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

23 мар 2023 08:30:00 Источник Nasdaq GlobeNewswire

Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients

23 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

03 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire